{"id":"gsk2245035-nasal-spray-solution","safety":{"commonSideEffects":["Nasal discomfort","Headache","Nasopharyngitis"]},"_chembl":{"chemblId":"CHEMBL2108251","moleculeType":"Oligosaccharide"},"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"TLR7 (Toll-like receptor 7)","explanation":"GSK2245035 is a selective TLR7 agonist that stimulates innate immune responses. By activating TLR7, it promotes interferon and cytokine production, potentially shifting immune responses away from allergic Th2-type reactions toward Th1-type responses, which may reduce allergic inflammation in the nasal passages.","oneSentence":"GSK2245035 activates Toll-like receptor 7 (TLR7) to modulate immune responses in the nasal mucosa."},"_scrapedAt":"2026-03-28T02:39:57.553Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123887,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"Fluticasone propionate","brand":"Flonase","company":"GlaxoSmithKline","rationale":"Intranasal corticosteroid for allergic rhinitis treatment"},{"name":"Azelastine","brand":"Astelin","company":"Meda Pharmaceuticals","rationale":"Intranasal antihistamine for allergic rhinitis"},{"name":"Mometasone furoate","brand":"Nasonex","company":"Merck","rationale":"Intranasal corticosteroid for allergic rhinitis"}],"description":"GSK2245035 is an investigational nasal spray solution developed by GlaxoSmithKline that reached Phase 2 clinical trials. As a TLR7 agonist, it was explored for potential treatment of allergic rhinitis and respiratory conditions by modulating immune responses in the nasal mucosa.","indications":{"approved":[{"status":"investigational","condition":"Allergic rhinitis","patientPopulation":"Adult patients with seasonal or perennial allergic rhinitis"}]},"trialDetails":[{"nctId":"NCT02833974","phase":"PHASE2","title":"Effect of the GSK2245035 on the Allergen-induced Asthmatic Response","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-12-05","conditions":"Asthma","enrollment":36},{"nctId":"NCT03707678","phase":"PHASE2","title":"A Safety and Efficacy Study of Intranasal GSK2245035 in Adults With Allergic Asthma","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2019-01-21","conditions":"Asthma","enrollment":""},{"nctId":"NCT01607372","phase":"PHASE2","title":"A Study to Investigate the Safety and Pharmacodynamics of Repeat Intranasal Administration of the TLR7 Agonist GSK2245035 in Subjects With Respiratory Allergies","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-04","conditions":"Asthma and Rhinitis","enrollment":18},{"nctId":"NCT01788813","phase":"PHASE2","title":"To Investigate the Safety, Pharmacodynamics and Effect on Allergic Reactivity of the Toll-like Receptor 7 (TLR7) Agonist GSK2245035 in Subjects With Respiratory Allergies","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-03","conditions":"Mild Asthma and Allergic Rhinitis","enrollment":42}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"GSK2245035 Nasal Spray Solution","genericName":"GSK2245035 Nasal Spray Solution","companyName":"GlaxoSmithKline","companyId":"gsk","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}